Work

Clinical Management of Respiratory Adverse Events Associated With Amikacin Liposome Inhalation Suspension: Results From a Patient Survey

Year: 2020

Type: article

Abstract: complex lung disease treated with amikacin liposome inhalation suspension (ALIS) at 2 clinics in the United States were surveyed to assess the frequency and management of ALIS-associated respiratory adverse events. Most respondents experienced these events, but management through physician-guided measures (eg, bronchodilator use, oral rinses, and/or temporary dosing adjustments) resulted in symptomatic improvement.

Source: Open Forum Infectious Diseases

DOI: 10.1093/ofid/ofaa079

Authors: Colin Swenson, Nicole C Lapinel, Juzar Ali

Institutions: Emory University, Louisiana State University Health Sciences Center New Orleans

Language: English

Topic: Inhalation and Respiratory Drug Delivery

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,053